Patents Assigned to Pfizer
  • Patent number: 4727159
    Abstract: Antifungal 1-[3-(substituted)-2-hydroxy-2-(perfluoroalkyl)-propyl]triazole derivatives wherein the 3-propyl substituent represents optionally substituted phenoxy, heteroaryloxy, alkylthio, alkylsulfinyl, alkylsulfonyl or optionally substituted carbamoyl.
    Type: Grant
    Filed: September 5, 1986
    Date of Patent: February 23, 1988
    Assignee: Pfizer Inc.
    Inventors: Kenneth Richardson, Peter J. Whittle
  • Patent number: 4725599
    Abstract: Certain trans-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]thieno[3,2-d]pyrimidin-4(3H )-one and furo[3,2-d]pyrimidin-4(3H)-one derivatives, a method of using same as anticoccidial agents, intermediates therefor, and a process for certain intermediates therefor.
    Type: Grant
    Filed: September 8, 1986
    Date of Patent: February 16, 1988
    Assignee: Pfizer Inc.
    Inventors: Edward A. Glazer, James W. McFarland
  • Patent number: 4725616
    Abstract: 1,3-Dicarboxamidooxindoles as antiinflammatory agents prepared by reaction of the 1-carbamoyloxindole with an isocyanate or by aminolysis of the corresponding alkyl 1-carbamoyloxindole-3-carboxylate.
    Type: Grant
    Filed: January 20, 1987
    Date of Patent: February 16, 1988
    Assignee: Pfizer Inc.
    Inventor: Saul B. Kadin
  • Patent number: 4725678
    Abstract: Certain 2-substituted-2-penem-3-carboxylic acid compounds and pharmaceutically-acceptable salts thereof can be prepared from the appropriate xanthate or trithiocarbonate by desulfurization and addition of an electrophilic sulfur compound followed by halogenation and ring closure. The corresponding desulfurized and halogenated olefinic intermediates are disclosed.
    Type: Grant
    Filed: April 4, 1986
    Date of Patent: February 16, 1988
    Assignee: Pfizer Inc.
    Inventor: Ernest S. Hamanaka
  • Patent number: 4723010
    Abstract: Chloromethyl group substituted heterocyclic compounds of the formulae ##STR1## wherein X is O or S;Y together with the two carbons to which Y is attached forms phenyl, pyridyl or pyrimidyl, each of which may be substituted by R;R is one of iodo or trifluoromethylthio or one or two of fluoro, chloro, bromo, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl or trifluoromethyl; andR.sup.1 is hydrogen or R, are prepared by reacting a bifunctional compound of the formulae ##STR2## with a 2-chloro-1,1,1-tri(C.sub.1 -C.sub.6)alkoxyethane. Most of the compounds of formulae I and II are novel. These compounds are intermediates of use in the preparation of compounds having pharmaceutical activity. The 2-chloro-1,1,1-tri(C.sub.1 -C.sub.6)alkoxyethanes are prepared from the corresponding tri(C.sub.1 -C.sub.6)alkoxyethanes by chlorination with N-chlorosuccinimide or with chlorine in pyridine and a chlorohydrocarbon cosolvent.
    Type: Grant
    Filed: November 7, 1985
    Date of Patent: February 2, 1988
    Assignee: Pfizer Inc.
    Inventors: Banavara L. Mylari, William J. Zembrowski
  • Patent number: 4721712
    Abstract: Certain 2-oxindole-1-carboxamide compounds having an acyl substituent at the 3-position, and also on the carboxamide nitrogen atom, are inhibitors of the cyclooxygenase (CO) and lipoxygenase (LO) enzymes, and are useful as analgesic agents and anti-inflammatory agents in mammalian subjects. These 2-oxindole-1-carboxamide compounds are of particular value for acute administration for ameliorating pain in human patients recovering from surgery or trauma, and also for chronic administration to human subjects for alleviating the symptoms of chronic diseases, such as rheumatoid arthritis and osteoarthritis. Certain 2-oxindole-1-carboxamide compounds unsubstituted at C-3, but having an acyl substituent on the carboxamide nitrogen atom, are useful as intermediates to the aforementioned analgesic and anti-inflammatory agents.
    Type: Grant
    Filed: November 13, 1984
    Date of Patent: January 26, 1988
    Assignee: Pfizer Inc.
    Inventor: Saul B. Kadin
  • Patent number: 4718911
    Abstract: A three-component acetabular cup assembly for receiving and releasably retaining the femoral head component of a prosthesis, said cup assembly comprising an outer metal shell, a cup-shaped inner bearing of substantially rigid plastic fixedly secured within said metal shell, and a locking ring made from the same plastic as the inner bearing; the outer surface of the bearing and the inner surface of the locking ring having cooperating configurations forming a secure but releasable latch.
    Type: Grant
    Filed: February 19, 1986
    Date of Patent: January 12, 1988
    Assignee: Pfizer Hospital Products Group Inc.
    Inventor: Robert V. Kenna
  • Patent number: 4716900
    Abstract: An improved intraintestinal bypass graft for attachment in the lumen of a resectioned intestine or duct upstream of the anastomosis site in order to protect the healing anastomosis comprises an elongated tube formed of a thin, highly flexible, water-impervious wall material terminating at its distal end in a short, reduced diameter nipple. The surgical procedure for implanting the bypass graft can be simplified and shortened in time by readily fitting the distal nipple over one end of an elongated pliable leader, or alternatively over the terminal anvil nut of a circular anastomosis surgical stapler, and then drawing the leader or stapler body through the patient's anus to pull the distal end of the bypass graft out of the anus. The need to tie the distal end of the bypass graft to the leader or surgical stapler is eliminated.
    Type: Grant
    Filed: May 9, 1986
    Date of Patent: January 5, 1988
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Biagio Ravo, Thomas E. Sloane, Jr., Christine L. Regan
  • Patent number: 4716113
    Abstract: An improved process for preparing (4S)-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione (sorbinil) or its (2R)-methyl derivative (2-methylsorbinil) is disclosed herein, starting from p-fluorophenol in each instance. The final products obtained have known pharmaceutical value as agents for the control of certain chronic diabetic complications. Key steps concerned with the process involve converting p-fluorophenol into the appropriate .beta.-(4-fluorophenoxy)alkane halide, followed by amidoalkylation with N-benzoyl or N-(lower alkanoyl)-.alpha.-hydroxyglycine to form an intermediate 2-amidoalkylated derivative thereof, and then dehydration and spiroalkylation of said intermediate by treatment with a dehydrating agent and a base to yield a spiroalkylated azlactone compound.
    Type: Grant
    Filed: March 31, 1986
    Date of Patent: December 29, 1987
    Assignee: Pfizer Inc.
    Inventor: Frank J. Urban
  • Patent number: 4716231
    Abstract: A novel process for chlorinating 2-methoxynicotinic acid at the 5-position of the molecule is disclosed. The process involves the use of an alkali metal hypochlorite as the chlorinating agent in a homogeneous aqueous solvent system. The compound so produced, 5-chloro-2-methoxynicotinic acid, is known to be useful as an intermediate leading to various oral hypoglycemic agents of the benzenesulfonylurea class.
    Type: Grant
    Filed: April 27, 1987
    Date of Patent: December 29, 1987
    Assignee: Pfizer Inc.
    Inventor: Carl J. Goddard
  • Patent number: 4715855
    Abstract: A fluid drainage system includes a suction chamber and a collection chamber. The suction chamber includes a suction regulator comprised of first and second chambers separated by a divider. An opening in the divider has a biased closing member associated therewith for opening or closing the opening according to the pressure differential between the chambers. A dash pot is connected to the closing member for damping the force on the closing member. The drainage system further includes devices for measuring the patient airflow, patient negativity and imposed suction. Those devices consist of diaphragms having dials connected thereto such that movement of the diaphragm results in movement of the dial and thereby indicating a change in one of the above noted variables. As an alternative, the drainage system includes a venturi meter for measuring airflow. Finally, the system contains an anti-spill device that prevents the spilling of fluids from the collection chamber to other chambers in the device.
    Type: Grant
    Filed: August 20, 1984
    Date of Patent: December 29, 1987
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Nicholas F. D'Antonio, Nicholas J. D'Antonio
  • Patent number: 4714761
    Abstract: A process for the preparation of penicillanic acid 1,1-dioxide and esters thereof readily hydrolyzable in vivo, which comprises oxidation of a 6,6-dihalopenicillanic acid, or an ester thereof readily hydrolyzable in vivo, to the corresponding 6,6-dihalopenicillanic acid 1,1-dioxide or ester thereof, followed by dehalogenation (e.g. by hydrogenolysis). The 6,6-dihalopenicillanic acid 1,1-dioxides and esters thereof readily hydrolyzable in vivo are novel intermediates. Penicillanic acid 1,1-dioxide, and esters thereof readily hydrolyzable in vivo, are known compounds which are useful as beta-lactamase inhibitors and for enhancing the effectiveness of certain beta-lactam antibiotics (e.g. the penicillins) in the treatment of bacterial infections in mammals, particularly humans.
    Type: Grant
    Filed: July 25, 1986
    Date of Patent: December 22, 1987
    Assignee: Pfizer Inc.
    Inventors: Ronnie D. Carroll, Robert A. Volkmann
  • Patent number: 4714603
    Abstract: A precipitated calcite of substantially spherical morphology having an average spherical diameter of from 2 to 10 microns and a specific surface area of from 1 to 15 square meters per gram is prepared by introducing carbon dioxide gas into an aqueous slurry of calcium hydroxide containing dissolved polyphosphate in the amount of from 0.1 to 1.0 percent, calculated as grams of phosphorus per 100 grams of the calcite equivalent of the calcium hydroxide, the starting temperature of the carbonation being 15.degree. to 50.degree. C. The spherical calcite is particularly suitable for use in dull finish coated paper.
    Type: Grant
    Filed: May 8, 1986
    Date of Patent: December 22, 1987
    Assignee: Pfizer, Inc.
    Inventor: Dennis B. Vanderheiden
  • Patent number: 4714468
    Abstract: A dispersion strengthened cobalt-chromium-molybdenum alloy produced by gas atomization containing a fine oxide dispersion, and characterized, after fabrication by gas atomization, thermomechanical processing and further high temperature exposure, by excellent corrosion resistance, high fatigue strength, high ductility and high temperature stability; a process for producing said alloy and prostheses formed from said alloy.
    Type: Grant
    Filed: January 27, 1987
    Date of Patent: December 22, 1987
    Assignee: Pfizer Hospital Products Group Inc.
    Inventors: Kathy K. Wang, Larry J. Gustavson, John H. Dumbleton
  • Patent number: 4714469
    Abstract: A spinal implant adapted to replace a disc between adjacent vertebrae having a predetermined thickness and profile chosen to match the space between said vertebrae and characterized by elongated protuberances adapted to be located in grooves drilled in said vertebrae and a porous coating on at least a portion of its surface. A method and apparatus for placement of said spinal implant are also disclosed.
    Type: Grant
    Filed: February 26, 1987
    Date of Patent: December 22, 1987
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventor: Robert V. Kenna
  • Patent number: 4711882
    Abstract: A series of novel octahydro-6-azaindole dipeptide derivatives have been prepared, including their pharmaceutically acceptable salts and bioprecursors therefor. These particular compounds are inhibitors of the angiotensin converting enzyme and are therefore useful in therapy for the treatment of certain cardiovascular disorders, including heart failure and hypertension. Preferred member compounds include 1-[N-(1-S-ethoxycarbonyl-3-phenylpropyl)-S-alanyl]-2-S-carboxy-6-(N-methyl carbamoyl)-octahydro-6-azaindole, 1-[N-(1-S-ethoxycarbonyl-3-phenylpropyl-S-alanyl]-2-S-carboxy-6-methanesul phonyl-octahydro-6-azaindole and 1-[N-(1-carboxy-3-phenylpropyl)-S-lysyl]-2-carboxy-6-methanesulphonyl-octa hydro-6-azaindole, respectively. Methods for preparing these compounds from known starting materials are provided.
    Type: Grant
    Filed: December 19, 1985
    Date of Patent: December 8, 1987
    Assignee: Pfizer Inc.
    Inventors: Simon F. Campbell, Ryszard J. Kobylecki
  • Patent number: 4711888
    Abstract: 2-Amino-4-substituted-5-(hydroxy or alkoxy)pyrimidines, which may be 6-substituted, and derivatives thereof are inhibitors of leukotriene synthesis and are therefore useful for the treatment of pulmonary, inflammatory, allergic and cardiovascular diseases. The compounds are also cytoprotective and therefore useful in the treatment of peptic ulcers.
    Type: Grant
    Filed: July 24, 1985
    Date of Patent: December 8, 1987
    Assignee: Pfizer Inc.
    Inventors: Frederick J. Walker, John L. LaMattina
  • Patent number: 4710537
    Abstract: Substantially homogeneous acrylate/maleate copolymers of number average molecular weight of 500 to 5000 are prepared by copolymerizing 35 to 65 mole percent acrylic or methacrylic acid with 65 to 35 mole percent maleic anhydride at 80.degree. to 150.degree. C. in the presence of a polymerization initiator and a chain-transfer solvent such that both the monomers and the formed polymer remain in solution and the mole ratio of the acrylic or methacrylic acid monomer to the maleic anhydride monomer in the solvent is maintained below about 0.2 throughout the polymerization. The copolymers in hydrolyzed form are employed at a level of from about 0.1 to 100 ppm for prevention of alkaline calcium and magnesium scale formation, such as during seawater evaporative desalination.
    Type: Grant
    Filed: October 11, 1985
    Date of Patent: December 1, 1987
    Assignee: Pfizer Inc.
    Inventor: Stanley W. Walinsky
  • Patent number: 4710507
    Abstract: A heterocyclic-substituted 2-quinolone compound of the formula: ##STR1## or a pharmaceutically-acceptable salt thereof, wherein "Het" is an optionally substituted 5-or 6-membered monocyclid aromatic heterocyclic group attached by a carbon atom to the 5-, 6-, 7- or 8- position of the quinolone nucleus; R, which is attached to the 5-, 6-, 7- or 8- position, is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulphinyl, C.sub.1 -C.sub.4 alkylsulphonyl, halo, CF.sub.3, hydroxy, hydroxymethyl, or cyano; R.sup.1 is hydrogen, cyano (C.sub.1 -C.sub.4 alkoxy)carbonyl, C.sub.1 -C.sub.4 alkyl, nitro, halo, --NR.sup.3 R.sup.4 or --CONR.sup.3 R.sup.4 where each of R.sup.3 and R.sup.4 is hydrogen or C.sub.1 -C.sub.4 alkyl or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic group optionally containing a further heteroatom or group selected from O, S and N--R.sup.5 where R.sup.
    Type: Grant
    Filed: December 18, 1984
    Date of Patent: December 1, 1987
    Assignee: Pfizer Inc.
    Inventors: Simon F. Campbell, David A. Roberts
  • Patent number: 4708132
    Abstract: A device for affixing a pretensioned ligament or tendon prosthesis to a bone of a patient includes a hollow elongated sleeve adapted to fit within a through drill hole in the bone and a cooperating wedge. A portion of the bore of the hollow sleeve is tapered with decreasing bore cross-sectional thickness towards the front end of the elongated sleeve. Th wedge is shaped so that a portion of a ligament or tendon prosthesis can be securely trapped between the wedge and the inner wall of the sleeve when the wedge is fully advanced forwardly within the sleeve. The device also includes a locking nut or ferrule for releasably locking the sleeve and wedge together with the wedge fully advanced within the sleeve, and a releasable bolt/washer assembly for preventing the prosthesis from being pulled forwardly through the drill hole in the patient's bone. The device is easy to use and provides a highly secure fixation of the pretensioned prosthesis.
    Type: Grant
    Filed: January 24, 1986
    Date of Patent: November 24, 1987
    Assignee: Pfizer-Hospital Products Group, Inc.
    Inventor: Thomas A. Silvestrini